((自动化翻译由路透提供,请见免责声明 ))
路透12月18日 -
美国制药商默克 周三与汉寿制药 签署了一项价值高达20亿美元的协议,开发中国生物技术公司的肥胖症药物并将其商业化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.